Stimulus! This pharmaceutical stock far exceeds the five grain liquid, taking down the share price king of Sichuan shares

Pharmaceutical Network Pharmaceutical Stock Market" Recently, the leading liquor companies' wuliang has become the focus of the attention of the shareholders, the market value once exceeded 700 billion yuan, the stock price continued to riseAt this time, a pharmaceutical unit - Kanghua Bio has attracted the attention of the industryOn June 16th Kanghua Bio, which landed on the company's board, closed its 15th one-word rally on July 8th, closing at 384.8 yuan, with a turnover rate of 1.1%Industry analysts believe that from the turnover rate, the stock still has room to riseKanghua bio issue price of 70.37 yuan, a profit of 15.72 million yuan, which is also the year is very profitable new sharesas of the morning of July 9, Kanghua Bio far exceeded the five grain liquid, took the position of The King of Sichuan sharesAt present, Kanghua Bio's share price remains at more than 400 yuan, and advanced into the Top 10 A sharespublic information shows that Chengdu Kanghua Biological Products Co., Ltdwas established in 2004The company's main business products include freeze-dried human rabies vaccine (human duolobin cells) and ACYW135 group meningococcal polysaccharide vaccine, of which freeze-dried human rabies vaccine (human diphmyloid cells) as the company's core productsrabies, also known as water-phosphoric disease, is a natural or animal-derived infectious disease caused by rabies virus infection, with a fatality rate of close to 100%Rabies vaccine is a preparation for the control and prevention of rabiesAmong them, human diploblast rabies vaccine by the World Health Organization called "the golden standard of rabies prevention" vaccine, with small adverse reactions, high immunogenicity advantagesChina-Thai Securities Research Report analysis pointed out that Kanghua biological is the domestic first and currently only one manufacturer of human dipoblast rabies vaccine vaccine enterprises, the company through independent research and development to break the domestic rabies vaccine has been using animal cells to prepare rabies vaccine technology limitations, follow-up with the expansion of production capacity sales is expected to gradually increaseAccording to a prospectus previously issued by Kanghua Bio, the IPO raised 1.056 billion yuan for the construction of the first phase of the Wenjiang Vaccine Production Base and the research and development center and the replenishment of working capital related to its main business Through the implementation of the fund-raising project, Kanghua biofreeze-dried human rabies vaccine production capacity will increase by 6 million units per year After the project is fully post-natal, the company's total production capacity of the freeze-dried human rabies vaccine will reach 11 million units/year , the ACYW135 meningococcal polysaccharide vaccine is also a major product of Kanghua Bio This product is used to prevent the prevalence of meningococcal meningococcal amyeurine amyelitis in groups A, C, Y and W135 July 8, Kanghua Bio issued a 2020 mid-year results forecast, the first half of the net profit is expected to reach 1.80 to 185 million yuan, an increase of 1.12 to 1.18 times, basic earnings per share of 3.00 to 3.08 yuan financial data show that the company's performance has grown rapidly in recent years, with operating income increasing from RMB93 million in 2016 to RMB555 million in 2019, and net profit from RMB665.79 million in 2016 to RMB187 million in 2019 In the first quarter of this year, the company achieved operating income of 157 million yuan, an increase of 20.4% YoY, and net profit of 64.8757 million yuan, an increase of 82.6% YoY it is worth mentioning that the industry generally believes that the company's stock surge beneficiaries are undoubtedly the real controller Wang Zhentao, which owns 24.91 percent of Kanghua Bio, Wang Zhentao's stock market value has risen from 1.5 billion yuan on the day of the listing to 5.754 billion yuan , Wang Zhentao's other identity is "China Shoe King", directly or indirectly holding 40.06 percent of the A-share company Okang International Affected by e-commerce and other factors, the data show that in 2019, Okang International's operating income was RMB2.726 billion, down 10.41% YoY, while net profit was RMB0.22 billion, down 83.57% YoY.